Clinical Trials Logo

Amphetamine-related Disorders clinical trials

View clinical trials related to Amphetamine-related Disorders.

Filter by:

NCT ID: NCT00267657 Active, not recruiting - Clinical trials for Amphetamine-Related Disorders

A Phase 1 Parallel-Group, Double-Blind, Placebo-Controlled Cardiovascular and Behavioral Study Assessing Interactions Between Single Doses of Oral Reserpine and Intravenous Methamphetamine - 1

Start date: January 2004
Phase: Phase 1
Study type: Interventional

In this parallel group clinical pharmacology laboratory experiment, we will assess pharmacodynamic interactions (with a focus on cardiovascular effects) of a 15 mg intravenous methamphetamine dose and single oral doses of reserpine (0.5 and 1.0 mg) or placebo.

NCT ID: NCT00265278 Active, not recruiting - Clinical trials for Amphetamine-Related Disorders

Assessment of Interactions Between Intravenous Methamphetamine and Modafinil - 1

Start date: March 2005
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the potential interactions between intravenous methamphetamine and oral Modafinil.

NCT ID: NCT00254306 Completed - Clinical trials for Amphetamine-Related Disorders

Functional Brain Imaging in Recreational Users of Ecstasy

Start date: January 2006
Phase: N/A
Study type: Observational

Recreational use of "ecstasy" (MDMA; 3,4-methylenedioxymethamphetamine) is associated with long-lasting effects on metabolism in the human brain. The investigators propose to investigate whether chronic use of "ecstasy" is associated with impairment in motor skills and function of the dopaminergic system in recreational users of "ecstasy" compared with healthy volunteers. This will be done by scanning control subjects and "ecstasy" users at baseline and after performing on a motorbike riding computer game, while imaging dopamine in vivo with I123-IBZM (a D2 receptor radiotracer), using single photon emission computed tomography (SPECT).

NCT ID: NCT00248092 Completed - Clinical trials for Substance-Related Disorders

Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in Adults With Histories of Stimulant Abuse

Start date: January 2006
Phase: Phase 1/Phase 2
Study type: Interventional

This research is being done to evaluate if NRP104 is a safe drug. The other purpose is to learn if NRP104 produces a high and any other effects like amphetamine and other stimulant drugs that are abused. This information will give some indication if NRP104 can be abused. NRP104 is an investigational drug. This means that it has not been approved by the U.S. Food and Drug Administration (FDA). Healthy people, between the ages of 18 and 55 with histories of substance abuse that include stimulant drugs, may join. Amphetamines are drugs that are used most often to treat attention deficit hyperactivity disorder (ADHD) in children, to treat narcolepsy (excessive sleepiness) and for weight loss.

NCT ID: NCT00247572 Completed - Clinical trials for Substance-Related Disorders

Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories

Start date: September 2005
Phase: Phase 2
Study type: Interventional

This research is being done to evaluate if NRP 104 is a safe drug. The other purpose is to learn if NRP104, when injected into a vein, produces a high and any other effects like amphetamine and other stimulant drugs that are abused. This information will give some indication if NRP104 can be abused. Healthy people, between the ages of 18 and 55 with histories of substance abuse that include stimulant drugs, may join. Amphetamines are drugs that are used most often to treat attention deficit hyperactivity disorder (ADHD) in children, to treat narcolepsy (excessive sleepiness) and for weight loss.

NCT ID: NCT00158197 Completed - Clinical trials for Amphetamine-related Disorders

Long-term Behavior Change - 1

Start date: December 2004
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if different reinforcement procedures (i.e., schedules) produce different patterns of long-term abstinence from methamphetamine. We anticipate that the three contingency management conditions will promote longer periods of abstinence in the year following treatment relative to the standard control group. Furthermore, we predict that the intermittent reinforcement procedures will produce longer periods of continued abstinence (i.e., long-term behavior change) in the year following treatment than the continuous reinforcement procedure. Finally, we predict that the intermittent unpredictable schedule will produce longer lasting behavior change than the intermittent predictable schedule. Methamphetamine use will be measured using urine toxicology and self-report of methamphetamine use.

NCT ID: NCT00123370 Active, not recruiting - Clinical trials for Amphetamine Dependence

Trial of Modafinil for Methamphetamine Dependence

Start date: July 2006
Phase: Phase 2
Study type: Interventional

The study aims to evaluate the safety and efficacy of modafinil (200 mg/day) over 10 weeks plus a tailored cognitive behavioural therapy program in the treatment of methamphetamine dependence.

NCT ID: NCT00100074 Active, not recruiting - Clinical trials for Amphetamine-Related Disorders

To Assess the Safety and Tolerability of 7.5, 15 and 30 mg of Sublingual Lobeline. - 1

Start date: September 2004
Phase: Phase 1
Study type: Interventional

To assess the safety and tolerability of 7.5, 15 and 30 mg of sublingual lobeline.

NCT ID: NCT00089440 Active, not recruiting - Clinical trials for Amphetamine-Related Disorders

Assessment of Interactions Between Methamphetamine and Aripiprazole - 1

Start date: June 2004
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the interactions between intravenous methamphetamine and aripiprazole.

NCT ID: NCT00069251 Completed - Clinical trials for Amphetamine-Related Disorders

Bupropion for the Treatment of Methamphetamine Dependence - 1

Start date: July 2003
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of bupropion in reducing methamphetamine use in subjects with methamphetamine dependence